Based on different parameters calculated from CGM data, the present study demonstrated that the Equil patch insulin pump has similar efficacy in clinical practice as the traditional MMT‐712 insulin pump, which has been shown to be effective and is widely used in clinical practice for patients with type 1 and type 2 diabetes, not only for controlling glucose variability but also for reducing hyperglycemia, as well as in managing hypoglycemic episodes in T2DM patients, indicating that the Equil patch insulin pump is a reliable tool for the glycemic management of diabetes mellitus. This evidence concerns the gene INS and diabetes mellitus.